NEW YORK (GenomeWeb) – Having recently published a multi-center clinical validation study of its blood test for early detection of colorectal cancer, Swiss molecular diagnostics firm Novigenix is now looking to expand the market for the assay in its home country and throughout the rest of Europe over the next year.

Novigenix's assay, called Colox, is unique in that it combines a 29-gene host immune response panel with a pair of tumor-derived protein biomarkers to detect not only early-stage colorectal cancer, but also large adenomatous polyps that can be precursors to cancer.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

A trial upgrade to 360Dx Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try 360Dx Premium now.

Already a 360Dx Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.